The EGFR Polymorphism rs884419 is Associated With Freedom From Recurrence in Patients With Resected Prostate Cancer

Journal of Urology

Volumn 183, Issue 5, 2010, Pages 2062-2069

  Perez, Carmen A ^a   Chen, Heidi ^a   Shyr, Yu ^a   Courtney, Regina ^a   Zheng, Wei ^a   Cai, Qiuyin ^a   Hwang, Misun ^a   Jaboin, Jerry ^a   Schleicher, Stephen ^a   Moretti, Luigi ^a   Wills, Marcia ^a   Smith, Joseph A ^a   Lu, Bo ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

biological markers; genes, erbB 1; polymorphism, genetic; prostate; prostatic neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; GENETIC ANALYSIS; GENETIC REGULATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 77950502168     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.12.098     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43
2. Ettinger D.S., Bepler G., Bueno R., et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4 (2006) 548
3. Rocha-Lima C.M., Soares H.P., Raez L.E., et al. EGFR targeting of solid tumors. Cancer Control 14 (2007) 295
4. Di Lorenzo G., Tortora G., D'Armiento F.P., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8 (2002) 3438
5. Cross M., and Dexter T.M. Growth factors in development, transformation, and tumorigenesis. Cell 64 (1991) 271
6. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159
7. Prenzel N., Fischer O.M., Streit S., et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8 (2001) 11
8. Milas L., Fan Z., Andratschke N.H., et al. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58 (2004) 966
9. Nasu S., Ang K.K., Fan Z., et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 51 (2001) 474
10. Araujo A., Ribeiro R., Azevedo I., et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 12 (2007) 201
11. Qian W., Liu J., Jin J., et al. Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk Res 31 (2007) 329
12. Wolff H., Saukkonen K., Anttila S., et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58 (1998) 4997
13. Kumar V.L., Majumder P.K., and Kumar V. Observations on EGFR gene amplification and polymorphism in prostatic diseases. Int Urol Nephrol 32 (2000) 73
14. Browning IV R.E., Li H., Shinohara E.T., et al. ATM polymorphism IVS62+60G>A is not associated with disease aggressiveness in prostate cancer. Urology 67 (2006) 1320
15. Hallahan D., Geng L., Qu S., et al. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3 (2003) 63
16. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 57 (1995) 289
17. The International HapMap Project. Nature 426 (2003) 789
18. Barrett J.C., Fry B., Maller J., et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263
19. Cartharius K., Frech K., Grote K., et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21 (2005) 2933
20. National Comprehensive Cancer Network Practice Guidelines in Oncology™, version 1.2008. http://www.nccn.org/professionals/physician_gls/PDF/prostate Accessed 2008
21. AJCC Cancer Staging Manual (2002), Springer, New York 309-316
22. West A.G., and Fraser P. Remote control of gene transcription. Hum Mol Genet 14 (2005) R101
23. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83
24. Muntener M., Epstein J.I., Hernandez D.J., et al. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53 (2008) 767
25. Sarkar S., Davies J.E., Huang Z., et al. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 282 (2007) 5641
26. Kesarwani P., Ahirwar D.K., Mandhani A., et al. Association between -174 G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol 27 (2008) 505
27. Narita N., Yuasa T., Tsuchiya N., et al. A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer 8 (2008) 224
28. Burri R.J., Stock R.G., Cesaretti J.A., et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 170 (2008) 49
29. Peters C.A., Stock R.G., Cesaretti J.A., et al. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 752
30. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433